Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T19615
|
||||
Former ID |
TTDR01234
|
||||
Target Name |
Granulocyte colony-stimulating factor
|
||||
Gene Name |
CSF3
|
||||
Synonyms |
G-CSF; Lenograstim; Pluripoietin; CSF3
|
||||
Target Type |
Successful
|
||||
Disease | Aplastic anemia [ICD9: 284; ICD10: D60-D61] | ||||
Neutropenia [ICD9: 288; ICD10: D70] | |||||
Neutropenia; Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Function |
Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes.
|
||||
BioChemical Class |
Cytokine: interleukin
|
||||
UniProt ID | |||||
Sequence |
MAGPATQSPMKLMALQLLLWHSALWTVQEATPLGPASSLPQSFLLKCLEQVRKIQGDGAA
LQEKLVSECATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQG LLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRR AGGVLVASHLQSFLEVSYRVLRHLAQP |
||||
Structure |
1HMC; 3UEZ; 3UF2; 4ADF; 4FA8; 1CD9; 1GNC; 1PGR; 1RHG; 2D9Q
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Interleukin-3 | Drug Info | Approved | Aplastic anemia | [551871] |
Neugranin | Drug Info | Preregistration | Neutropenia | [547546] | |
DA-3031 | Drug Info | Phase 3 | Neutropenia | [524038] | |
LA-EP2006 | Drug Info | Phase 3 | Neutropenia | [523772] | |
MK-4214 | Drug Info | Phase 3 | Neutropenia | [551956] | |
SPI-2012 | Drug Info | Phase 3 | Neutropenia; Breast cancer | [549072] | |
F-627 | Drug Info | Phase 2 | Neutropenia | [525287] | |
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
PI3K-Akt signaling pathway | |||||
Jak-STAT signaling pathway | |||||
Hematopoietic cell lineage | |||||
Malaria | |||||
NetPath Pathway | IL1 Signaling Pathway | ||||
TNFalpha Signaling Pathway | |||||
TCR Signaling Pathway | |||||
WikiPathways | Cytokines and Inflammatory Response | ||||
Hematopoietic Stem Cell Differentiation | |||||
References | |||||
Ref 523772 | ClinicalTrials.gov (NCT01516736) Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim. U.S. National Institutes of Health. | ||||
Ref 524038 | ClinicalTrials.gov (NCT01674855) Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia. U.S. National Institutes of Health. | ||||
Ref 525287 | ClinicalTrials.gov (NCT02521441) A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy. | ||||
Ref 547546 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017176) | ||||
Ref 549072 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031953) | ||||
Ref 527761 | Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol. 1992 Apr;14(3):421-30. | ||||
Ref 532495 | Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects. Clin Drug Investig. 2013 Nov;33(11):817-24. | ||||
Ref 544453 | Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia pastoris. PLoS One. 2014; 9(12): e115840. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.